| |
 |
| Online: |
| ¬ User: 0 |
| ¬ Gäste: 96 |
| Besucher: |
| ¬ Heute: 731 |
| ¬ Gestern: 995 |
| ¬ Gesamt: 2015000 |
| ¬ ø Tag: 242.86 |
| Max.: |
| ¬ pro Tag: 3598 |
| ¬ Online: 540 |
| |
|
 |
|
|
|
| Forum |
| » Hauptforum » Forum: Allgemein » Thread: Renub Research | Spinal Muscular Atrophy |
| |
| [ Neuer Eintrag - letzter Post ] |
| Thread |
 Seite: « 1 » |
| #1 |
» 17.07.19 08:05h |
|
|
Spinal muscular atrophy is a genetic disorder disease that causes weakness and wasting (atrophy) it appears mostly in newborn children. Loss of specialized nerve cells (motor neurons) that control muscle movement is the reason for this disease. Due to this disease, an individual cannot walk, eat and breathe properly. The muscle weakness usually worsens as the child grows up. SMA disease can occur in any race or gender. 1 out of 11,000 babies is affected by this disease.  There are 4 types of SMA disease: Type 1, Type 2, Type 3 and Type 4 among these, Type 1 is a most common type. Spinal muscular atrophy type I (also called Werdnig-Hoffmann disease), it occurs at birth or after a few months of birth. it is a severe form of the disorder with muscle weakness in the child. Type II (also called Dubowitz disease), it occurs in children aged between 6 months to 12 months. Type III (also called Kugelberg-Welander disease), it occurs in early childhood. Type IV is rare and begins in early adulthood. According to Renub Research analysis, the United States is the biggest market for SMA, growth of global  Spinal Muscular Atrophy Market is forecasted to grow with a CAGR of 14.26 percent in upcoming years. Biogen Inc., Roche AG, Novartis AG and Cytokinetics Inc are some big healthcare companies involved in the treatment of spinal muscular atrophy. Request a free sample copy of the report: https://www.renub.com/request-brochure-page.php?gturl=spinal-muscular-atrophy-market-p.php Spinal Muscular Atrophy (SMA) type 1 develop in less than 6 months of new born children in which patients are not in position to sit in their lifetime and normally they die within 6 months. In spinal muscular atrophy type 2, patients can sit but cannot walk. Type 2 is developed between 6-18 months of the new born children. Spinal muscular atrophy Type 3 patients can sit and walk and it developed when children age is less than 18 months. Spinal muscular atrophy Type 4 can develop during the adulthood. Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years At present only Biogen's Spinraza is approved for the treatment of spinal muscular atrophy patients in the various parts of the globe such as United States, Europe, and Japan etc. Other companies are also working for new drugs development and they hope to enter in the market place very soon as their drugs are in Phase III clinical trials. Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=spinal-muscular-atrophy-market-p.php By Country - Market Segmentation Spinal muscular atrophy market by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is a leading market place due to increasing number of treated Patients, favorable reimbursement policies and increase in healthcare expenditure. By Total & Treated Patients - Population Segmentation Spinal muscular atrophy Total & Treated Patients by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is dominating in the treated SMA patients globally. By Drugs - Market Segmentation The report by Renub Research studies the spinal muscular atrophy six drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) details with present and estimated global sales. Contact Us: Email: info@renub.com Phone: +1-678-302-0700 Web: www.renub.com Address: 225 Kristie Ln, Roswell, GA 30076, United States Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others. |
|
|
| |
 |
|
|
| Seite: « 1 » |
| [ Neuer Eintrag - letzter Post ] |
|
 |
|
|
vs. sf-c
33:15
8:40
vs. GD
halflife2